Assessing Antiviral Treatments in Early Symptomatic RSV

PHASE2RecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
Respiratory Syncytial VirusRespiratory Syncytial Virus, Human
Interventions
DRUG

Ribavirin

"Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day"

DRUG

Molnupiravir

Oral molnupiravir 800mg BD for 5 days

DRUG

Favipiravir

Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days

Trial Locations (2)

10400

RECRUITING

Faculty of Tropical Medicine, Mahidol University, Bangkok

01000

RECRUITING

Laos-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane

All Listed Sponsors
lead

University of Oxford

OTHER